CD4 and myeloid sarcoma: Here, we provide evidence that the lectican CSPGs deposited in MS lesions11,12, and specifically versican-V1, have this capacity as shown by increased Th17 generation in culture when CD4+ T cells are polarized in the presence of a mixed CSPG preparation and purified versican-V1.